AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05291156
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week.
Trial: NCT05291156
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
Trial: NCT05386758
Drug: Molnupiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Four 200 mg capsules administered orally as a single dose
Trial: NCT06538233
Drug: Non buffered articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
Trial: NCT05991232
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Trial: NCT05728775
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
Trial: NCT05728775
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is administered intravenously for induction and maintenance of general anesthesia.
Trial: NCT05867849
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabinoid
Trial: NCT05029466
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
Trial: NCT06200155
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05226598
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
Trial: NCT05226598
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
Trial: NCT05226598
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Trial: NCT05226598
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
Trial: NCT05226598
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
Trial: NCT05980806
Drug: Selinexor 60 mg
RxNorm normalized name: selinexor 60 MG
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive selinexor 60 mg oral tablets QW.
Trial: NCT05980806
Drug: Selinexor 40 mg
RxNorm normalized name: selinexor 40 MG
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive selinexor 40 mg oral tablets QW.
Trial: NCT05980806
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
Trial: NCT05980806
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive pacritinib 200 mg twice daily.
Trial: NCT05980806
Drug: Momelotinib
RxNorm normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive momelotinib 200 mg once daily.
Trial: NCT04177004
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04177004
Drug: Goat Milk
RxNorm normalized name: GOAT MILK
DrugBank: Goat milk (DB10542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given human lysozyme goat milk PO
Trial: NCT04177004
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04177004
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and PO
Trial: NCT05501704
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT05501704
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT05501704
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous (under the skin) injection
Trial: NCT05501704
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally
Trial: NCT04774003
Drug: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
Trial: NCT04774003
Drug: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
Trial: NCT05819892
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05819892
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05819892
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05819892
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05359276
Drug: Olipudase alfa
RxNorm normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZ402665
Trial: NCT00002326
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002326
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05914363
Drug: Routine deworming
RxNorm normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
Trial: NCT00002016
Drug: Sevirumab
RxNorm normalized name: Sevirumab
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05030766
Drug: Nicotine Replacement Therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 weeks of Nicotine replacement patches
Trial: NCT05857163
Drug: Rifasutenizol capsules
RxNorm normalized name: Rifasutenizol
DrugBank: Rifasutenizol (DB18981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg, BID, taken orally within half an hour after breakfast and dinner.
Trial: NCT05857163
Drug: Rabeprazole sodium enteric-coated tablets
RxNorm normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg, BID, taken orally within half an hour before breakfast and dinner.
Trial: NCT05857163
Drug: Amoxicillin Capsules
RxNorm normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g, BID, taken orally within half an hour after breakfast and dinner.
Trial: NCT05857163
Drug: Bismuth potassium citrate placebo capsules
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BID, taken orally within half an hour before breakfast and dinner.
Trial: NCT05857163
Drug: Bismuth potassium citrate capsules
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg, BID, taken orally within half an hour before breakfast and dinner.
Trial: NCT05857163
Drug: Rifasutenizol placebo capsules
DrugBank: Rifasutenizol (DB18981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, taken orally within half an hour before breakfast and dinner.
Trial: NCT06016517
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg subcutaneously weekly
Trial: NCT06016517
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg subcutaneously every 2 weeks
Trial: NCT06016517
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg orally once daily with subcutaneous placebo injection every 2 weeks
Trial: NCT06016517
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4mg per kg IV every 4 weeks
Trial: NCT05571878
Drug: Humalog
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
Trial: NCT05856357
Drug: Sulfadoxine pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Trial: NCT06499090
Drug: Mirtazapine 30 MG
RxNorm normalized name: mirtazapine 30 MG
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
Trial: NCT05418868
Drug: Cabotegravir 200 mg/mL
RxNorm normalized name: cabotegravir 200 MG/ML
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB 200 mg/mL will be administered.
Trial: NCT05418868
Drug: Cabotegravir >=400 mg/mL
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB \>=400 mg/mL will be administered by IM or SC injection.
Trial: NCT05418868
Drug: Cabotegravir Formulation I
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB Formulation I will be administered by IM injection.
Trial: NCT05418868
Drug: RPV
RxNorm normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPV will be administered by IM injection.
Trial: NCT06468202
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to 81mg Aspirin
Trial: NCT06468202
Drug: Aspirin 162 mg
RxNorm normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to 162mg Aspirin
Trial: NCT05787860
Drug: Ruxolitinib 1.5% Cream
RxNorm normalized name: RUXOLITINIB 1.5% CREAM,TOP
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ruxolitinib 1.5% cream twice daily for 4 weeks
Trial: NCT06539091
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Trial: NCT06539091
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Trial: NCT05561205
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylphenidate
Trial: NCT04871191
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
Trial: NCT04871191
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of 162 mg per week
Trial: NCT04871191
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: - Tofacitinib, administered orally at a dose of 5 mg twice a day. Tofacitinib will start at week 0. Treatment will be continued until week 52
Trial: NCT00002083
Drug: Peptide T
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04644185
Drug: SCTA01
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL SCTA01 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SCTA01 .KAPPA.-CHAIN, DIMER
DrugBank: Upanovimab (DB16505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
Trial: NCT05782816
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose oxytocin
Trial: NCT05782816
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose oxytocin
Trial: NCT06173986
Drug: PD-1inhibitor
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
Trial: NCT06173986
Drug: nab-paclitaxel + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
Trial: NCT05345327
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SGLT2 inhibitor
Trial: NCT05345327
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin
Trial: NCT04753918
Drug: Porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
Trial: NCT04753918
Drug: Ethiodized oil
RxNorm normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
Trial: NCT05074602
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
Trial: NCT05689021
Drug: Abiraterone Acetate/Niraparib
RxNorm normalized name: Abiraterone Acetate/Niraparib 500 MG-50 MG Oral Tablet
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05689021
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05636514
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily
Trial: NCT04971395
Drug: XTMAB-16 2 mg/kg
DrugBank: XTMAB-16 (DB18380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 mg/kg
Trial: NCT04971395
Drug: XTMAB-16 4mg/kg
DrugBank: XTMAB-16 (DB18380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 4 mg/kg
Trial: NCT05442775
Drug: Reldesemtiv
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05843669
Drug: Guafenesin tablets
RxNorm normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
Trial: NCT05715671
Drug: esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
Trial: NCT05869591
Drug: Apixaban 5 MG [Eliquis]
RxNorm normalized name: apixaban 5 MG [Eliquis]
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
Trial: NCT05869591
Drug: Edoxaban 60 MG [Lixiana]
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
Trial: NCT04903470
Drug: Bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
Trial: NCT04903470
Drug: Atropin
RxNorm normalized name: Atropin
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
Trial: NCT00496236
Drug: TNFerade biologic
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04711148
Drug: orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib is a white, round, uncoated tablet
Trial: NCT06461182
Drug: Ga-68-CXCR4
RxNorm normalized name: Ga 68 DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
Trial: NCT06113016
Drug: Fisetin
RxNorm normalized name: FISETIN
DrugBank: Fisetin (DB07795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04310020
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04919252
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.
Trial: NCT06491082
Drug: Cisplatin, Carboplatin, Paclitaxel, Docetaxel
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solid cancer Patients receiving any one drug or in combination